GEN Exclusives

More »

GEN News Highlights

More »
Nov 21, 2011

Valeant to Buy iNova for A$625M Up Front

  • Valeant is to acquire pharmaceutical sales firm iNova Pharmaceuticals, for A$625 million (almost $617.75 million) up front, and potentially another A$75 million (about $74.12 million) in milestones related to pipeline projects, product registrations, and overall revenues.

    iNova sells and distributes a range of prescription and OTC products in Australasia, Asia-Pacific, South Africa, the Americas, and other international markets. The firm’s strategy is to take on late clinical-phase and fully developed products requiring registration or for which registration is under way or completed.

    iNova in addition has product development expertise, which is focused on new product introductions life cycle management, product quality, and drug formulation developments. The firm’s revenues are expected to reach approximately A$200 million in 2011, with revenues having grown at a rate of some 10% annually over the last four years.

    Valeant has completed a swathe of acquisitions this year. Most recently the firm completed the first stage of its C$0.85 per share acquisition of Canadian consumer health products firm Afexa.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?